AnaptysBio, Inc.'s rosnilimab shows promise in RA & ulcerative colitis, targeting $20B+ markets. Phase 2b results highlight ...

AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is ...

Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox™ platform-based photoimmunotherapy, today announced that its third drug candidate, RM-0256, has been ...

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and ...

AnaptysBio announces positive results from phase 2b trial of rosnilimab to treat rheumatoid arthritis: San Diego Thursday, June 5, 2025, 18:00 Hrs [IST] AnaptysBio, Inc., a clinic ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.

The New Drug Application (NDA) for the combination of fruquintinib and sintilimab for locally advanced or metastatic renal ...

Two drugs. Two strategies. One industry in the middle of a rewiring.

AnaptysBio (ANAB) hosted a webcast to discuss positive rosnilimab Phase 2b rheumatoid arthritis results and featured two leading rheumatologists, ...

Casma Therapeutics, Inc., a biotechnology company engaging the autophagy and lysosomal systems to develop innovative new medicines, today announced the nomination of its first development candidate, ...

China NMPA accepts Hutchmed & Innovent’s NDA for fruquintinib in combo with sintilimab to treat advanced renal cell carcinoma: Hong Kong, Shanghai Friday, June 6, 2025, 09:00 Hr ...